<DOC>
	<DOCNO>NCT00777062</DOCNO>
	<brief_summary>To evaluate efficacy VIVITROL ( naltrexone extended-release injectable suspension ) treatment co-occurring cocaine alcohol dependence</brief_summary>
	<brief_title>VIVITROL Treatment Cocaine Alcohol Dependence</brief_title>
	<detailed_description>This Phase II double-blind randomize controlled clinical pilot study . The exploratory objective propose study examine 2-group design ass efficacy naltrexone extended-release injectable suspension ( VIVITROLâ„¢ ) compare placebo . Safety measure collect weekly medical management ( MM ) medical practitioner , include adverse event concomitant med . The psychosocial treatment Cognitive Behavioral Coping Skills Therapy ( CBT ) . Subjects 80 men woman current DSM-IV diagnosis alcohol dependence cocaine dependence randomize receive either VIVITROL placebo ( 40 subject per group ) . All subject receive weekly session CBT MM . The study length subject comprise 1-3 week screen , 8-week double-blind , placebo-controlled trial MM CBT ( medication phase ) , end medication visit . Primary Exploratory Objectives : - To compare medication group ' rate cocaine abstinence , determine urine assay benzoylecgonine ( BE ) , primary metabolite cocaine . This cross-checked participant ' self-reports cocaine use Time-Line Follow Back ( TLFB ) ( Sobell &amp; Sobell , 1992 ) . - To compare medication group ' rate abstinence drinking , clinically significant drinking , measure TLFB . Secondary Exploratory Objectives : - To evaluate medication group ' report crave cocaine alcohol , measure score Penn Alcohol Craving Scale Minnesota Cocaine Craving Scale medication treatment phase . - To compare woman 's report medication tolerance naltrexone extended-release injectable suspension versus high dose oral naltrexone report recently publish pilot trial high dose naltrexone dual cocaine alcohol dependence ( Pettinati et al. , 2008 ) .</detailed_description>
	<mesh_term>Alcoholism</mesh_term>
	<mesh_term>Cocaine-Related Disorders</mesh_term>
	<mesh_term>Ethanol</mesh_term>
	<mesh_term>Cocaine</mesh_term>
	<mesh_term>Naltrexone</mesh_term>
	<criteria>Inclusion Criteria 1 . Males female , 18 65 year old . 2 . Meets DSMIV criterion Cocaine Dependence , determine Structured Clinical Interview DSMIV ( SCID ) . 3 . Meets DSMIV criterion Alcohol Dependence , determine Structured Clinical Interview DSMIV ( SCID ) . 4 . Meets follow drinking criterion measure Timeline Followback ( TLFB ) ( Sobell , 1995 ) 1. drank within 30 day intake day , 2. report minimum XX standard alcoholic drink consecutive 30day period 90day period prior start intake , 3. 2 day heavy drinking 5 . In past 30 day prior consent , use less $ cocaine . 6 . Live within commutable distance Treatment Research Center ( TRC ) Penn/VA Center Studies Addiction , University Pennsylvania . We define distance within service area Septa , within hour drive , distance patient Principal Investigator ( PI ) find acceptable . 7 . Understands sign inform consent . 8 . Three consecutive day abstinence alcohol , Clinical Institute Withdrawal Scale Alcohol ( CIWAAR ) ( Sullivan , 1989 ) score eight . 4.2 1 . Positive urine drug screen and/or current DSMIV diagnosis psychoactive substance dependence cocaine , alcohol , nicotine dependence , determine SCID . 2 . Concomitant treatment psychotropic medication , include opioid analgesic . 3 . Patients mandate treatment base upon legal decision condition employment . 4 . Current severe psychiatric symptom , e.g. , psychosis , dementia , suicidal homicidal ideation , mania depression require antidepressant therapy opinion Principal Investigator ( PI ) . 5 . Taken investigational medication within past 30 day . 6 . History within six month prior randomization significant heart disease ( arrhythmia require medication , WolffParkinsonWhite Syndrome , angina pectoris , document history myocardial infarction , heart failure ) . These review casebycase basis : EKG 1st degree heart block , sinus tachycardia , leave axis deviation , nonspecific ST T wave change allow ; liver function test [ LFTs ] &lt; 3 x ULN acceptable ) . 7 . Known hypersensitivity naltrexone , PLG , carboxymethylcellulose , component diluent . 8 . Subjects BMI 40 , determine Body Mass Index Table , distribution adipose tissue would great risk serious injection site reaction , base clinical judgment . Participants BMI 30 additional screening procedure conduct determine inclusion study . These procedure include additional screening measurement waisthip ratio participant BMI 30 . Males waist hip ratio &gt; 0.9 female waist hip ratio &gt; 0.85 referred investigator final decision study inclusion . If ratio &lt; 0.9 men &lt; 0.85 woman eligible study inclusion without action . 9 . Patients serious illness may require hospitalization study . 10 . Female subject pregnant lactating , female subject childbearing potential use acceptable method birth control . Acceptable method birth control include : 11 . Clinical laboratory test ( CBC , blood chemistry , urinalysis ) outside normal limit clinically unacceptable Principal Investigator . 12 . Current physiological opioid dependence . 13 . Experiencing acute opiate withdrawal . 14 . Likely receive schedule surgery , may require treatment opioid analgesic .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>alcohol</keyword>
	<keyword>cocaine</keyword>
	<keyword>addiction</keyword>
	<keyword>alcoholism</keyword>
	<keyword>substance dependence</keyword>
	<keyword>substance abuse</keyword>
</DOC>